Pipeline
Molecular Insight is focused on the critical unmet diagnostic and therapeutic needs of the prostate cancer patient. We are targeting the development of a proprietary small-molecule chemistry platform to improve detection of primary and metastatic prostate cancer and to provide a novel systemic radiotherapy for relapsed and metastatic prostate cancer.
| Product Candidate | Indication | Status |
|---|---|---|
| Diagnostic | ||
| 99mTc-trofolastat | Rapid, sensitive detection, staging and monitoring of primary and metastatic prostate cancer in soft tissue and bone by targeting prostate specific membrane antigen (PSMA) |
Completed Phase 1 proof of concept and radiation dosimetry clinical trials in prostate cancer patients and healthy volunteers Investigational New Drug application (IND) allowed in Q2 2012. Multi-center international Phase 2 clinical trial in high risk prostate cancer patients undergoing prostatectomy began in Q3 2012 |
| THERAPEUTIC | ||
| 131I-MIP-1095 | Systemic radiotherapy for metastatic prostate cancer by targeting PSMA with 131I labeled small molecules | Demonstrated preclinical efficacy in rodent models of human prostate cancer IND submission targeted for Q4 2012 Phase 1 dose escalation clinical trial planned to initiate in 2013 |
| Discovery | ||
| MIP-1500 | Second generation systemic radiotherapy for prostate cancer enabling alternative beta and alpha emitting radionuclides to enhance tumor control and ease of use | Identified several classes of high affinity lead PSMA inhibitors Ongoing optimization of pharma-cokinetics |
| MIP-2100 | Radiation sensitizers for use in combination with 131I-MIP-1095 to prolong duration, increase response, and enhance the efficacy of prostate cancer radiotherapy | Evaluation in preclinical models of human prostate cancer for synergy of several classes of molecular targeted chemotherapeutic agents in combination with radiotherapy |